Dividend compounder review

DNLI

Denali Therapeutics Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score26.50/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 7.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 11.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 5.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-512.5M
Free Cash Flow$-422.1M
FCF Covers DividendUnknown
Debt / Equity4.32
P/E-
Revenue Growth 5Y204.7%
Net Margin0.0%
ROE-49.6%
Price vs Trend12.0%
3Y Return-25.1%
5Y Return-71.0%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Debt to equity is elevated at 4.32.
Dividend diary

Activity record

DNLI dividend review warning Warning · Warning

Debt to equity is elevated at 4.32.